Evidence map›Paper›PMID 34536489›Full record

ArticleJournal of neuroscience methods2021

A new strategy to increase RNA editing at the Q/R site of GluA2 AMPA receptor subunits by targeting alternative splicing patterns of ADAR2.

Helena Chaytow, Ilda Sethw Hassan, Sara Akbar, Linda Popplewell, George Dickson, Philip E Chen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroscience methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Helena ChaytowCentres of Gene and Cell Therapy and Biomedical Sciences, Department of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK.
Ilda Sethw HassanCentres of Gene and Cell Therapy and Biomedical Sciences, Department of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK.
Sara AkbarCentres of Gene and Cell Therapy and Biomedical Sciences, Department of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK.
Linda PopplewellCentres of Gene and Cell Therapy and Biomedical Sciences, Department of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK.
George DicksonCentres of Gene and Cell Therapy and Biomedical Sciences, Department of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK.
Philip E ChenCentres of Gene and Cell Therapy and Biomedical Sciences, Department of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK. Electronic address: philip.chen@rhul.ac.uk.
Royal Holloway University of London · GB

Funding

Motor Neurone Disease Association CHEN/OCT11/859-792
6 · The paper itself

Abstract

backgroundThe GluA2 subunit of AMPA receptors (AMPARs) undergoes RNA editing at a specific base mediated by the enzyme ADAR2, changing the coded amino acid from a glutamine to arginine at the so-called Q/R site, which is critical for regulating calcium permeability. ADAR2 exists as multiple alternatively-spliced variants within mammalian cells with differing editing efficiency. NEW

methodIn this study, phosphorodiamidate morpholino oligomers (PMOs) were used to increase Q/R site editing, by affecting the alternative splicing of ADAR2.

resultsPMOs targeting the ADAR2 pre-mRNA transcript successfully induced alternative splicing around the AluJ cassette leading to expression of a more active isoform with increased editing of the GluA2 subunit compared to control. COMPARISON WITH EXISTING METHOD(S): Previously PMOs have been used to disrupt RNA editing via steric hindrance of the GluA2 RNA duplex. In contrast we report PMOs that can increase the expression of more catalytically active variants of ADAR2, leading to enhanced GluA2 Q/R RNA editing.

conclusionsUsing PMOs to increase Q/R site editing is presented here as a validated method that would allow investigation of downstream cellular processes implicated in altered ADAR2 activity.

Indexed as

Receptors, AMPARNA EditingAdenosine DeaminaseAlternative SplicingAnimalsRNA-Binding ProteinsAdenosine DeaminaseReceptors, AMPARNA-Binding ProteinsADAR2AMPARsAmyotrophic lateral sclerosisAntisense oligonucleotidesNeurodegeneration

Identifiers

PMID34536489
PMCPMC8573265
OpenAlexW3200543989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.